Oncology
Promising Directions in Myeloma and Lymphoproliferative Disorders: Approaching Resistance, Retreatment, and Maintenance Through Novel Clinical Pathways
Chapters
Exploring Synergistic Therapies in Multiple Myeloma
- Steven P. Treon, MD, MA, PhD
|
|
|
Steven P. Treon, MD, MA, PhD, discusses the developments in therapy for multiple myeloma and potential additive or synergistic effects of agents used in combination.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the synergistic mechanisms of action of combination regimens in the treatment of newly diagnosed and relapsed/refractory multiple myeloma
- Identify novel agents in development for the treatment of multiple myeloma
- Summarize the data concerning the effectiveness of combination regimens for the treatment of multiple myeloma
|
Rational Approaches for Frontline Treatment of Multiple Myeloma
|
|
|
Asher Chanan-Khan, MD, discusses the developments in management strategies for the frontline treatment of multiple myeloma.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe frontline treatment options available for elderly patients who are not candidates for transplantation
- Recall data summarizing the use of novel targeted agents in combination with existing chemotherapeutic regimens for frontline treatment of multiple myeloma
- Summarize the data available concerning the use of steroid-free regimens as frontline treatment in multiple myeloma
|
Emerging Strategies for the Treatment of Relapsed/Refractory Multiple Myeloma
|
Program Director: Andre Goy, MD, MPH
|
|
Sagar Lonial, MD, discusses developments in management strategies for the treatment of relapsed/refractory multiple myeloma.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize the data available concerning the use of thalidomide and its analogues in the treatment of relapsed/refractory multiple myeloma
- Recall data summarizing the use of proteasome inhibition in combination with existing chemotherapeutic regimens for treatment of relapsed/refractory multiple myeloma
- Describe the rationale for combining immunomodulatory therapy with proteasome inhibition in the treatment of relapsed/refractory multiple myeloma
|
Exploring Synergistic Therapies in Lymphoproliferative Disorders
|
Program Director: Andre Goy, MD, MPH
|
|
Michele Ghielmini, MD, reviews current and emerging therapies in lymphoproliferative diseases and describes how they may be combined for synergistic therapeutic effect.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify the classes of drugs available for the treatment of lymphoma
- Discuss the mechanisms of action of drugs used in the treatment of lymphoma
- Review preclinical evidence of synergy between approved or investigational lymphoma therapies
|
State-of-the-Art Management of Follicular Lymphoma
|
Program Director: Andre Goy, MD, MPH
|
|
Read a discussion by Peter McLaughlin, MD, on current approaches to therapy for both previously untreated and relapsed follicular lymphoma.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe treatment choices for localized follicular lymphoma
- Explain how the Follicular Lymphoma International Prognostic Index score guides patient management
- Cite studies on rituximab maintenance vs retreatment
- List strategies for improving initial response to rituximab therapy
|
State-of-the-Art Management of Diffuse Large B-Cell Lymphoma
|
Program Director: Andre Goy, MD, MPH
|
|
Michael Pfreundschuh, MD, outlines the current management of diffuse large B-cell lymphoma and highlights some ongoing clinical trials investigating optimization of therapy.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Explain the importance of the International Prognostic Index in making treatment decisions for patients with diffuse large B-cell lymphoma
- List the treatment options available for young patients with diffuse large B-cell lymphoma
- Describe the impact of rituximab on the treatment of elderly patients with diffuse large B-cell lymphoma
- Discuss alternative strategies for optimizing rituximab dosing in patients with diffuse large B-cell lymphoma
|
State-of-the-Art Management of Mantle Cell Lymphoma
|
|
|
Andre Goy, MD, MPH, reviews current thinking on the clinical management of mantle cell lymphoma, including data presented at the 2007 hematology meeting.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss approaches to the treatment of patients with relapsed or refractory mantle cell lymphoma that take into account variables such as prior treatment and response
- Describe the etiology and biology of mantle cell lymphoma
- Cite novel biologic therapies in clinical testing for patients with mantle cell lymphoma
- Review the molecular pathways being targeted with emerging novel therapies
|
State-of-the-Art Management of Waldenström’s Macroglobulinemia
- Steven P. Treon, MD, MA, PhD
|
|
|
Steven P. Treon, MD, MS, PhD, discusses the developments in therapy for Waldenström’s macroglobulinemia and potential additive or synergistic effects of agents used in combination.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the role of mast cells in Waldenström’s macroglobulinemia and the potential for agents targeting these cells
- Recall data concerning the combination of targeted therapies with chemotherapy for upfront and salvage treatment of Waldenström’s macroglobulinemia
- Summarize the data about agents being studied for the prevention of Waldenström’s macroglobulinemia
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|